Autosomal dominant polycystic kidney disease
Conditions
Interventions
Group A:Glucosidorum Tripterygll Totorum+losartan potassium
Group B:Placebo + losartan potassium
Sponsors
Shanghai Changzheng Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18-70, both sexes; 2. Clinical and ultrasound diagnosis of ADPKD; 3. GFR >= 45 ml/min (CKD-EPI formula); 4. Total kidney volume growth rate >=3%(6months); 5. Positive result in urine protein qualitative test; 6. Written informed consent.
Exclusion criteria
Exclusion criteria: 1 .Known anaphylactic reaction to Triptolide; 2. Severe liver dysfunction with AST and/or ALT is more than 1.5 times of normal range; 3. Refractory hypertension(SBP>160mmHg or DBP>100mmHg after using more than two kinds of antihypertensive agents for at least one month); 4. Severe heart failure (NYHA III/IV),unstable angina,.myocardial infarction,left ventricular hypertrophy with ECG change, thromboembolic disease; 5. Diabetes mellitus without control; 6. Patients with a life threatening malignancy or infection; 7. Hypoleukemia(<3.0*10^9/L),anemia(hemoglobin<90g/L),active hemorrhage or other hematological system disease. 8. Drug or alcohol abuse, Psychiatric disorders and a;y condition that might prevent full comprehension of the purposes and risks of the study; 9. Pregnancy, lactation or child bearing potential and ineffective contraception; 10. Having taken part in other clinical trial in recent 3 months; 11. Investigators have evaluated that patient's condition is not suitable to attend the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change of Total kidney volume growth rate and kidney cyst index;the change of Proteinuria;the change of eGFR; | — |
Secondary
| Measure | Time frame |
|---|---|
| the change of blood routine examination,Blood fat test, Blood test for liver and renal function, CD4/CD8, cystatin; | — |
Countries
China
Contacts
Public ContactChanglin Mei
Outcome results
None listed